Mangalam Drugs & Organics Limited (BOM:532637)
India · Delayed Price · Currency is INR 30.27
+0.09 (0.30%)
At close: Jun 17, 2026
Mangalam Drugs & Organics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2,321 | 3,176 | 3,674 | 3,702 | 4,509 |
| 2,321 | 3,176 | 3,674 | 3,702 | 4,509 | |
Revenue Growth (YoY) | -26.91% | -13.55% | -0.77% | -17.89% | 18.66% |
Cost of Revenue | 1,569 | 1,702 | 2,472 | 2,536 | 3,101 |
Gross Profit | 752.57 | 1,474 | 1,201 | 1,166 | 1,408 |
Selling, General & Admin | 337.88 | 421.82 | 403.56 | 359.68 | 396.96 |
Other Operating Expenses | 556.09 | 690.5 | 623.42 | 550.29 | 520.32 |
Operating Expenses | 1,076 | 1,278 | 1,173 | 1,020 | 1,020 |
Operating Income | -323.63 | 195.61 | 27.98 | 146.34 | 387.99 |
Interest Expense | -162.08 | -111.8 | -104.09 | -89.21 | -72.02 |
Interest & Investment Income | - | 0.58 | 0.96 | 2.98 | 0.01 |
Other Non Operating Income (Expenses) | 0 | -37.27 | -35.06 | -37.94 | -39.59 |
EBT Excluding Unusual Items | -485.71 | 47.12 | -110.21 | 22.17 | 276.37 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.89 |
Gain (Loss) on Sale of Assets | - | 0.74 | -0.52 | -0.03 | - |
Pretax Income | -485.71 | 47.86 | -110.73 | 22.14 | 277.33 |
Income Tax Expense | -41.71 | -19.35 | -20.02 | 9.44 | 80.76 |
Net Income | -444 | 67.21 | -90.72 | 12.7 | 196.58 |
Net Income to Common | -444 | 67.21 | -90.72 | 12.7 | 196.58 |
Net Income Growth | - | - | - | -93.54% | -29.72% |
Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 |
Shares Change (YoY) | 0.00% | - | - | - | - |
EPS (Basic) | -28.05 | 4.25 | -5.73 | 0.80 | 12.42 |
EPS (Diluted) | -28.05 | 4.25 | -5.73 | 0.80 | 12.42 |
EPS Growth | - | - | - | -93.56% | -29.72% |
Free Cash Flow | -77.22 | 223.93 | -79.2 | 116.09 | -19.6 |
Free Cash Flow Per Share | -4.88 | 14.15 | -5.00 | 7.33 | -1.24 |
Gross Margin | 32.42% | 46.41% | 32.71% | 31.50% | 31.22% |
Operating Margin | -13.94% | 6.16% | 0.76% | 3.95% | 8.61% |
Profit Margin | -19.13% | 2.12% | -2.47% | 0.34% | 4.36% |
Free Cash Flow Margin | -3.33% | 7.05% | -2.16% | 3.14% | -0.43% |
EBITDA | -141.4 | 330.21 | 76.84 | 241.08 | 473.58 |
EBITDA Margin | -6.09% | 10.40% | 2.09% | 6.51% | 10.50% |
D&A For EBITDA | 182.23 | 134.6 | 48.86 | 94.74 | 85.6 |
EBIT | -323.63 | 195.61 | 27.98 | 146.34 | 387.99 |
EBIT Margin | -13.94% | 6.16% | 0.76% | 3.95% | 8.61% |
Effective Tax Rate | - | - | - | 42.63% | 29.12% |
Revenue as Reported | 2,329 | 3,187 | 3,687 | 3,727 | 4,512 |
Advertising Expenses | - | 15.95 | 12.85 | 13.56 | 24.44 |